Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 8/20 | 0.39 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.37 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.33 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7078035 | 0.80 | HSD11B1 (0.40) | HSD11B1SLC5A1SLC5A2 | |
| SCHEMBL6898757 | 0.79 | HSD11B1 (0.43) | HSD11B1HCAR3HCAR2 | |
| SCHEMBL6898977 | 0.79 | CHRNA1 (0.43) | HSD11B1SMN1; SMN2 | |
| SCHEMBL6891948 | 0.78 | HSD11B1 (0.42) | HSD11B1HCAR3HCAR2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6897736 | 0.78 | HSD11B1 (0.42) | HSD11B1HCAR3HCAR2 | |
| Hydrochloric Acid SCHEMBL6928573 | 0.77 | GRIN2D (0.35) | HSD11B1HCAR3HCAR2 | |
| SCHEMBL17812492 | 0.77 | HDAC4 (0.42) | HSD11B1 | |
| SCHEMBL23620372 | 0.76 | HSD11B1 (0.58) | HSD11B1SMN1; SMN2 | |
| SCHEMBL18905253 | 0.76 | HSD11B1 (0.38) | HSD11B1 | |
| SCHEMBL6376813 | 0.76 | MEN1 (0.46) | HSD11B1HCAR3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1143964-B1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RES LTD (GB) | 2004-03-24 | — | — | EP | disclosed |
| EP-1051392-B1 | ADAMANTANECARBOXIMIDAMIDE DERIVATIVES AND THEIR USE AS NMDA ANTAGONISTS | VERNALIS RES LTD (GB) | 2003-12-17 | — | — | EP | disclosed |
| US-6531511-B1 | N-methyl aspartate receptor antagonist | VERNALIS RESEARCH LIMITED (GB) | 2003-03-11 | — | — | US | disclosed |
| EP-1143964-A1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2001-10-17 | — | — | EP | disclosed |
| US-6262106-B1 | Adamantanecarboximidamide derivatives and their use as NMDA antagonists | VERNALIS RESEARCH LIMITED (GB) | 2001-07-17 | — | — | US | disclosed |
| EP-1051392-A1 | ADAMANTANECARBOXIMIDAMIDE DERIVATIVES AND THEIR USE AS NMDA ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2000-11-15 | — | — | EP | disclosed |
| WO-2000044371-A1 | 2-ADAMANTANEMETHANAMINE COMPOUNDS FOR TREATING ABNORMALITIES IN GLUTAMATERGIC TRANSMISSION | VERNALIS RESEARCH LIMITED (GB) | 2000-08-03 | — | — | WO | disclosed |
| WO-1999038841-A1 | ADAMANTANECARBOXIMIDAMIDE DERIVATIVES AND THEIR USE AS NMDA ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 1999-08-05 | — | — | WO | disclosed |